AMP German Cannabis Group and Eve & Co. have entered into a supply agreement for the purchase and export to Germany of European Union Good Manufacturing Practice (EU-GMP) medical cannabis flower. The first large import to Germany from Canada is expected before the end of 2020 with 50 to 100 kilograms and monthly imports of up to 100 kilograms to begin 2021.
Eve & Co. greenhouse cultivation facility is located in Strathroy, Ontario, Canada and received EU 'Certificate of GMP Compliance of a Manufacturer' ("EU GMP") from the Government of Upper Bavaria in Germany on March 6, 2020.
Dr. Stefan Feuerstein, Director and President of AMP, commented: "AMP has signed a supply purchase agreement with Canadian cannabis licence holder, Eve & Co. We are qualifying additional Canadian suppliers under the Covid-19 travel restrictions to prepare for higher demand from German patients in 2021 as doctors and pharmacists become more informed about the medical benefits of cannabis."
Dr. Feuerstein added, "AMP's Roundtable Series, which is available at amp-eu.de/roundtable, discusses medical cannabis developments and issues in Germany. In our first episode, AMP's Roundtable Series guest, Dr. Franjo Grotenhermen, a German medical doctor and a medical cannabis expert with a high reputation in Europe, joins me and moderator, Mr. Holger Scholze in an in-depth discussion about the current situation in Germany."
Ms. Melinda Rombouts, President and CEO of Eve & Co., commented: "We are among a small number of Canadian cannabis licence holders able to export to Germany and the EU. We are committed to servicing the European market with cannabis for medical purposes and have been ramping up our cultivation capacity in our greenhouse. Our agreement with AMP is another milestone in being a cannabis supplier for the EU, and we are looking forward to a fruitful collaboration."
For more information:
AMP German Cannabis Group
Charlottenstraße 59
10117 Berlin, Germany
investor@amp-eu.de
investor@amp-eu.com
amp-eu.com